Premium
Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience
Author(s) -
Desterro Joana,
McLornan Donal P.,
Curto Garcia Natalia,
O'Sullivan Jennifer,
Alimam Samah,
Keohane Clodagh,
Woodley Claire,
Francis Yvonne,
Kordasti Shahram,
Radia Deepti H.,
Harrison Claire N.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15968
Subject(s) - medicine , tolerability , hydroxycarbamide , cohort , aspirin , referral , surgery , adverse effect , family medicine , chemotherapy
Summary Standard first‐line therapy choice for essential thrombocythaemia ( ET ) requiring cytoreduction, supported by randomized trials, is low‐dose aspirin with hydroxycarbamide, but the role of recombinant interferon‐alfa ( IFN α)‐2a/2b and pegylated ( PEG )‐ IFN ‐α‐2a/2b is increasingly highlighted. Longer‐term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well‐annotated cohort of ET patients from a single referral centre undergoing therapy with either IFN α or ( PEG )‐ IFN ‐α‐2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long‐term therapy in a significant proportion of patients.